Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
Pancreatic cancer features elaborate mechanisms of immune evasion. The potential of new immune molecules was explored to restore the antitumor immune response. If these immune molecules are associated with poor survival, specific drugs could take effect. Here, we analyze the expression of VISTA, LAG...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2689 |
id |
doaj-6c49a7f497a44a8db306390c88eb15e0 |
---|---|
record_format |
Article |
spelling |
doaj-6c49a7f497a44a8db306390c88eb15e02021-06-01T01:37:30ZengMDPI AGCancers2072-66942021-05-01132689268910.3390/cancers13112689Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal AdenocarcinomaFelix C. Popp0Ingracia Capino1Joana Bartels2Alexander Damanakis3Jiahui Li4Rabi R. Datta5Heike Löser6Yue Zhao7Alexander Quaas8Philipp Lohneis9Christiane J. Bruns10on behalf of the PANCALYZE Study GroupDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyInstitute of Pathology, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyInstitute of Pathology, University of Cologne, 50937 Cologne, GermanyInstitute of Pathology, University of Cologne, 50937 Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, GermanyPancreatic cancer features elaborate mechanisms of immune evasion. The potential of new immune molecules was explored to restore the antitumor immune response. If these immune molecules are associated with poor survival, specific drugs could take effect. Here, we analyze the expression of VISTA, LAG3, IDO, and TIM3 on tumor-infiltrating lymphocytes (TILs) and its impact on patient survival. We analyzed 153 pancreatic cancer patients from the prospectively managed database of the multicentered PANCALYZE study. Immunohistochemistry on a tissue microarray assessed VISTA, LAG3, IDO, and TIM3 expression of TILs from the patients undergoing primary resection. Complementarily, we analyzed publicly available transcriptomic data (<i>n</i> = 903). Successful completion of chemotherapy, and lymph node status were independent predictors of survival in the multivariate analysis of the clinicopathologic parameters. Fifteen tumors were exclusively VISTA-positive, thirteen tumors expressed VISTA together with TIM3, and ten tumors expressed VISTA together with IDO. Patients featuring tumors with high numbers of IDO-positive TILs had better patient survival (<i>p</i> = 0.037). VISTA, LAG3, and TIM3 expression did not correlate with survival. The analysis of publicly available data did not show survival differences. Tumors rarely co-express more than two immune molecules at the same time, and VISTA is most frequently co-expressed. Although IDO generally inhibits T-cell proliferation, a high expression of IDO was associated with improved survival. We expect immune checkpoint inhibitors against VISTA, LAG3, and TIM3 to be inefficient in a clinical application.https://www.mdpi.com/2072-6694/13/11/2689pancreatic cancerimmune checkpointimmune moleculestumor-infiltrating lymphocytesIDOVISTA |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Felix C. Popp Ingracia Capino Joana Bartels Alexander Damanakis Jiahui Li Rabi R. Datta Heike Löser Yue Zhao Alexander Quaas Philipp Lohneis Christiane J. Bruns on behalf of the PANCALYZE Study Group |
spellingShingle |
Felix C. Popp Ingracia Capino Joana Bartels Alexander Damanakis Jiahui Li Rabi R. Datta Heike Löser Yue Zhao Alexander Quaas Philipp Lohneis Christiane J. Bruns on behalf of the PANCALYZE Study Group Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma Cancers pancreatic cancer immune checkpoint immune molecules tumor-infiltrating lymphocytes IDO VISTA |
author_facet |
Felix C. Popp Ingracia Capino Joana Bartels Alexander Damanakis Jiahui Li Rabi R. Datta Heike Löser Yue Zhao Alexander Quaas Philipp Lohneis Christiane J. Bruns on behalf of the PANCALYZE Study Group |
author_sort |
Felix C. Popp |
title |
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma |
title_short |
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma |
title_full |
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma |
title_fullStr |
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed |
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma |
title_sort |
expression of immune checkpoint regulators ido, vista, lag3, and tim3 in resected pancreatic ductal adenocarcinoma |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-05-01 |
description |
Pancreatic cancer features elaborate mechanisms of immune evasion. The potential of new immune molecules was explored to restore the antitumor immune response. If these immune molecules are associated with poor survival, specific drugs could take effect. Here, we analyze the expression of VISTA, LAG3, IDO, and TIM3 on tumor-infiltrating lymphocytes (TILs) and its impact on patient survival. We analyzed 153 pancreatic cancer patients from the prospectively managed database of the multicentered PANCALYZE study. Immunohistochemistry on a tissue microarray assessed VISTA, LAG3, IDO, and TIM3 expression of TILs from the patients undergoing primary resection. Complementarily, we analyzed publicly available transcriptomic data (<i>n</i> = 903). Successful completion of chemotherapy, and lymph node status were independent predictors of survival in the multivariate analysis of the clinicopathologic parameters. Fifteen tumors were exclusively VISTA-positive, thirteen tumors expressed VISTA together with TIM3, and ten tumors expressed VISTA together with IDO. Patients featuring tumors with high numbers of IDO-positive TILs had better patient survival (<i>p</i> = 0.037). VISTA, LAG3, and TIM3 expression did not correlate with survival. The analysis of publicly available data did not show survival differences. Tumors rarely co-express more than two immune molecules at the same time, and VISTA is most frequently co-expressed. Although IDO generally inhibits T-cell proliferation, a high expression of IDO was associated with improved survival. We expect immune checkpoint inhibitors against VISTA, LAG3, and TIM3 to be inefficient in a clinical application. |
topic |
pancreatic cancer immune checkpoint immune molecules tumor-infiltrating lymphocytes IDO VISTA |
url |
https://www.mdpi.com/2072-6694/13/11/2689 |
work_keys_str_mv |
AT felixcpopp expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT ingraciacapino expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT joanabartels expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT alexanderdamanakis expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT jiahuili expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT rabirdatta expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT heikeloser expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT yuezhao expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT alexanderquaas expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT philipplohneis expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT christianejbruns expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma AT onbehalfofthepancalyzestudygroup expressionofimmunecheckpointregulatorsidovistalag3andtim3inresectedpancreaticductaladenocarcinoma |
_version_ |
1721411902858330112 |